Innate Pharma announces that the U.S. FDA has lifted the partial suspension of the lacutamab clinical program, which had been decided on October 5, following the death of a patient in the TELLOMAK study.

This lifting of the suspension is based on the review of the fatal case, for which Innate, in collaboration with a steering committee of independent experts, concluded that there was no link between the death and lacutamab.

The lacutamab program is proceeding according to plan following the publication of the positive results in Sézary syndrome presented at the recent ASH 2023 annual meeting," comments Medical Director Sonia Quaratino.

Copyright (c) 2024 CercleFinance.com. All rights reserved.